Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,411 across all filing types
Latest filing 2025-09-29 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZN harmonises listing structure
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding a proposed change in the company's listing structure (harmonisation across LSE, STO, and NYSE). It explicitly mentions that a 'Circular incorporating a notice of General Meeting' has been published and provides links to where these documents can be found. Since the document itself is an announcement of the publication of these materials rather than the proxy statement or circular itself, it falls under the Report Publication Announcement (RPA) category.
2025-09-29 English
DIRECTOR/PDMR SHAREHOLDING
Regulatory Filings
2025-09-25 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically a Non-Executive Director acquiring shares. This falls under the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives.
2025-09-25 English
KOSELUGO RECOMMENDED FOR EU APPROVAL
Regulatory Filings
2025-09-22 English
TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP
Regulatory Filings
2025-09-22 English
Koselugo recommended for EU approval
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces a positive recommendation from the CHMP (Committee for Medicinal Products for Human Use) for the approval of the drug 'Koselugo' in the EU. This is a standard corporate regulatory announcement regarding product development and regulatory status, which falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or shareholder meeting categories.
2025-09-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.